Phase 3 Clinical Trials With Primary Completion Dates in October 2017

This is a list of Phase 3 trials with primary completion dates in October 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ARDXArdelyx, Inc.2017-10-01Phase 3NCT02727751A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
CPRXCatalyst Pharmaceuticals, Inc.2017-10-01Phase 3NCT02562066Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
EARSAuris Medical Holding AG2017-10-01Phase 3NCT02561091AM-111 in the Treatment of Acute Inner Ear Hearing Loss
INSMInsmed, Inc.2017-10-01Phase 3NCT02344004Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
MNKMallinckrodt plc2017-10-01Phase 3NCT02132195Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NBRVNabriva Therapeutics plc2017-10-01Phase 3NCT02813694Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
TAROTaro Pharmaceutical Industries Ltd.2017-10-01Phase 3NCT02595073Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis
TGTXTG Therapeutics, Inc.2017-10-01Phase 3NCT02301156Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
VICLVical Incorporated2017-10-01Phase 3NCT01877655A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)